Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION" OBTAINS APPROVAL FOR DRUG REGISTRATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION"

OBTAINS APPROVAL FOR DRUG REGISTRATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company") announces that "Moxifloxacin Hydrochloride and Sodium Chloride Injection", an anti-infective drug developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a subsidiary of the Company, has obtained approval for drug registration granted by the National Medical Products Administration of the People's Republic of China.

Moxifloxacin belongs to the fourth generation broad spectrum quinolone anti-infective drugs and has strong antibacterial activity. Moxifloxacin Hydrochloride and Sodium Chloride Injection has become the first-line drug for multidisciplinary anti-infective treatment and is widely used in respiratory, intensive care unit, surgery, obstetrics and gynecology, emergency and other departments. The drug is included in the 2017 National Drugs Catalogue for Medical Insurance and the 2018 National Essential Drugs Catalogue.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 9 March 2020

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.